cardiology
Medicines

After yet another failure, stem cell leaders double down

Despite an unrelieved history of negative trials, stem cell leaders continue to defend their field. In response to the failure of yet another cardiac stem clinical trial, Roberto Bolli, a prominent leader in the field, argued that it’s time for a “paradigm shift” in the field. We need more stem cell therapy, not less, he ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic